Get started
Author

Kei Fukami

Observed names: Fukami K, K Fukami, K. FUKAMI, K. Fukami, KEI FUKAMI, Kei FUKAMI, kei fukami
Observed institutions: Kurume University, Albert Einstein College of Medicine, Royal Children's Hospital, Baker Heart and Diabetes Institute, Kanazawa Medical University, The University of Melbourne, Friedrich-Alexander-Universität Erlangen-Nürnberg, Heidelberg University, Karolinska Institutet, Centre Hospitalier Universitaire de Bordeaux, Cardiovascular Institute Hospital, Kurume University Hospital, Kurume University Medical Center, Japanese Society of Nephrology, Juvenile Diabetes Research Foundation, Klinički bolnički centar Osijek, Okayama Saiseikai General Hospital, Murdoch Children's Research Institute, Affymax (United States), Chugai Pharmaceutical Co., Ltd. (Japan), University of Osijek, Kobe University, Showa Pharmaceutical University
ORCID: 0000-0002-5583-3996
Observed ORCID: 0000-0002-5583-3996
OpenAlex ID: A5029975728
RAGE-Induced Cytosolic ROS Promote Mitochondrial Superoxide Generation in Diabetes
2009 · Melinda T. Coughlan, David R. Thorburn, et al. · Journal of the American Society of Nephrology · 472
Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product–Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-α–Dependent Pathway
2007 · Vicki Thallas-Bonke, Suzanne R. Thorpe, et al. · Diabetes · 345
PDF
Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes
2011 · Sho-ichi Yamagishi, Sayaka Maeda, et al. · Biochimica et Biophysica Acta (BBA) - General Subjects · 295
AGEs activate mesangial TGF-β–Smad signaling via an angiotensin II type I receptor interaction
2004 · Kei Fukami, Seiji Ueda, et al. · Kidney International · 218
PDF
Role of AGEs-RAGE System in Cardiovascular Disease
2014 · Kei Fukami, Sho-ichi Yamagishi, et al. · Current Pharmaceutical Design · 193
Diabetic Nephropathy: Where Hemodynamics Meets Metabolism
2007 · J. Forbes, K. Fukami, et al. · Experimental and Clinical Endocrinology & Diabetes · 183
Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product–Induced Protein Arginine Methyltranferase-1 Expression
2012 · Ayako Ojima, Yuji Ishibashi, et al. · American Journal Of Pathology · 155
PDF
Molecular Mechanisms of Diabetic Nephropathy and Its Therapeutic Intervention
2007 · Sho-ichi Yamagishi, Kei Fukami, et al. · Current Drug Targets · 152
Role of AGEs in Diabetic Nephropathy
2008 · Kei Fukami, Sho-ichi Yamagishi, et al. · Current Pharmaceutical Design · 149
RAGE signaling regulates the progression of diabetic complications
2023 · Kensei Taguchi, Kei Fukami · Frontiers in Pharmacology · 138
PDF
Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications
2008 · Sho-ichi Yamagishi, Kazuo Nakamura, et al. · Expert Opinion on Investigational Drugs · 137
RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy
2017 · Takanori Matsui, Yuichiro Higashimoto, et al. · Diabetes · 126
Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications
2015 · Sho-ichi Yamagishi, Kei Fukami, et al. · Cardiovascular Diabetology · 125
PDF
Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease
2015 · Sho-ichi Yamagishi, Kei Fukami, et al. · International Journal of Cardiology · 109
Dimethylarginine Dimethylaminohydrolase Prevents Progression of Renal Dysfunction by Inhibiting Loss of Peritubular Capillaries and Tubulointerstitial Fibrosis in a Rat Model of Chronic Kidney Disease
2007 · Yuriko Matsumoto, Seiji Ueda, et al. · Journal of the American Society of Nephrology · 106
Protective role of pigment epithelium‐derived factor (PEDF) in early phase of experimental diabetic retinopathy
2009 · Yumiko Yoshida, Sho‐Ichi Yamagishi, et al. · Diabetes/Metabolism Research and Reviews · 105
Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis
2021 · Hiroaki Ogata, Masafumi Fukagawa, et al. · JAMA · 95
PDF
IL-1RI deficiency ameliorates early experimental renal interstitial fibrosis
2009 · Lynelle K. Jones, Kim M. O’Sullivan, et al. · Nephrology Dialysis Transplantation · 87
Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy
2022 · Sean J. Barbour, Rosanna Coppo, et al. · Kidney International · 84
PDF
Oral L-Carnitine Supplementation Increases Trimethylamine-N-oxide but Reduces Markers of Vascular Injury in Hemodialysis Patients
2015 · Kei Fukami, Sho-ichi Yamagishi, et al. · Journal of Cardiovascular Pharmacology · 84
DNA Aptamer Raised Against AGEs Blocks the Progression of Experimental Diabetic Nephropathy
2013 · Yusuke Kaida, Kei Fukami, et al. · Diabetes · 78
Role of Receptor for Advanced Glycation End Products (RAGE) and Its Ligands in Cancer Risk
2014 · Sho-ichi Yamagishi, Takanori Matsui, et al. · Rejuvenation Research · 71
Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction
2013 · Ryotaro Ando, Seiji Ueda, et al. · Diabetes and Vascular Disease Research · 68
Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice
2012 · Yoshimi Takamiya, Kei Fukami, et al. · Nephrology Dialysis Transplantation · 66
Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease
2007 · Seiji Ueda, Sho-ichi Yamagishi, et al. · Clinical and Experimental Nephrology · 65
Works count: 256
Citation count: 5,978
H-index: 39
I10-index: 99
Year
Topic
Type